Novel immunosuppressant improves kidney function and quality of life after transplantation
The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.
Read original article on The Medical News →Related news
-
Newly discovered protein controls the space between mitochondrial membranes
United Kingdom
-
LGBTQ+ college students facing discrimination report higher mental health risks
United Kingdom
-
Ancient virus may help explain differences in human and chimpanzee brains
United Kingdom
-
Movement helps people learn complex patterns more effectively, study finds
United Kingdom
-
Six-gene score could improve survival predictions for acute myeloid leukemia
United Kingdom
-
Study reveals how cancer cells survive chemotherapy in a zombie-like state
United Kingdom
-
Taurine helps regulate inflammation linked to aging, Yale study finds
United Kingdom
-
Nephrologist shortages linked to higher kidney disease mortality along US-Mexico borde
United Kingdom